EGFR and non-small cell lung carcinoma: DCB is regarded as a new way of treatment for this medical case.16 The U.S. Food and Drug Administration (FDA) accepted Pfizer's application for DCB as new drug and granted priority review for the first-line management of patients with locally advanced or metastatic NSCLC with EGFR-activating mutations.